Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 1, 2009

Mitsubishi Tanabe Gains Asian Rights to EnVivo’s Cognition-Enhancing Drug

  • Mitsubishi Tanabe Pharma (MTPC) licensed EnVivo Pharmaceuticals’ cognition-enhancing therapy for development and commercialization in Japan and other Asian countries. The candidate, EVP-6124, is in Phase IIa trials in the U.S.

    MTPC will pay an initial license fee as well as clinical, regulatory, and commercial milestones. EnVivo will also receive royalties on sales of EVP-6124 in the MTPC territory, which includes Japan, Korea, Taiwan, Indonesia, and other countries in Asia.

    MTPC plans on initiating Phase I trials during 2010. EVP-6124 is an alpha-7 nicotinic acetylcholine receptor agonist currently being tested by EnVivo in Alzheimer's and schizophrenia patients.

    EnVivo obtained exclusive rights to the alpha-7 agonist program and a related patent estate from Bayer Healthcare in November 2004.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »